Avestar Capital’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $661K | Buy |
3,604
+69
| +2% | +$12.7K | 0.04% | 294 |
|
|
2025
Q4 | $622K | Buy |
3,535
+913
| +35% | +$149K | 0.04% | 298 |
|
|
2025
Q3 | $367K | Sell |
2,622
-175
| -6% | -$23.7K | 0.02% | 385 |
|
|
2025
Q2 | $351K | Buy |
2,797
+622
| +29% | +$77.5K | 0.02% | 367 |
|
|
2025
Q1 | $298K | Sell |
2,175
-70
| -3% | -$10K | 0.03% | 377 |
|
|
2024
Q4 | $343K | Buy |
2,245
+58
| +3% | +$9.78K | 0.03% | 357 |
|
|
2024
Q3 | $424K | Sell |
2,187
-301
| -12% | -$63K | 0.04% | 282 |
|
|
2024
Q2 | $577K | Buy |
2,488
+454
| +22% | +$98.7K | 0.06% | 229 |
|
|
2024
Q1 | $439K | Sell |
2,034
-103
| -5% | -$24.1K | 0.05% | 255 |
|
|
2023
Q4 | $553K | Buy |
2,137
+105
| +5% | +$25.8K | 0.06% | 187 |
|
|
2023
Q3 | $522K | Buy |
2,032
+24
| +1% | +$6.42K | 0.07% | 163 |
|
|
2023
Q2 | $572K | Buy |
2,008
+134
| +7% | +$39.9K | 0.09% | 138 |
|
|
2023
Q1 | $521K | Buy |
1,874
+99
| +6% | +$27.4K | 0.09% | 142 |
|
|
2022
Q4 | $492K | Buy |
1,775
+14
| +0.8% | +$3.95K | 0.09% | 140 |
|
|
2022
Q3 | $470K | Sell |
1,761
-314
| -15% | -$66.7K | 0.12% | 130 |
|
|
2022
Q2 | $423K | Sell |
2,075
-659
| -24% | -$135K | 0.1% | 141 |
|
|
2022
Q1 | $576K | Buy |
2,734
+133
| +5% | +$28.9K | 0.09% | 207 |
|
|
2021
Q4 | $624K | Buy |
2,601
+703
| +37% | +$181K | 0.08% | 218 |
|
|
2021
Q3 | $537K | Buy |
1,898
+18
| +1% | +$5.9K | 0.07% | 268 |
|
|
2021
Q2 | $651K | Sell |
1,880
-116
| -6% | -$35.1K | 0.09% | 235 |
|
|
2021
Q1 | $534K | Buy |
1,996
+144
| +8% | +$38.8K | 0.12% | 175 |
|
|
2020
Q4 | $453K | Buy |
1,852
+84
| +5% | +$21.7K | 0.13% | 145 |
|
|
2020
Q3 | $454K | Sell |
1,768
-143
| -7% | -$39.9K | 0.15% | 122 |
|
|
2020
Q2 | $511K | Sell |
1,911
-259
| -12% | -$77.9K | 0.23% | 101 |
|
|
2020
Q1 | $687K | Buy |
2,170
+231
| +12% | +$70.1K | 0.38% | 70 |
|
|
2019
Q4 | $575K | Sell |
1,939
-167
| -8% | -$46.3K | 0.32% | 75 |
|
|
2019
Q3 | $490K | Sell |
2,106
-5
| -0.2% | -$1.16K | 0.3% | 75 |
|
|
2019
Q2 | $473K | Sell |
2,111
-98
| -4% | -$22.6K | 0.3% | 61 |
|
|
2019
Q1 | $502K | Sell |
2,209
-120
| -5% | -$37.8K | 0.33% | 58 |
|
|
2018
Q4 | $675K | Sell |
2,329
-150
| -6% | -$47.9K | 0.46% | 44 |
|
|
2018
Q3 | $852K | Buy |
2,479
+51
| +2% | +$17.6K | 0.49% | 37 |
|
|
2018
Q2 | $685K | Buy |
2,428
+287
| +13% | +$80.7K | 0.43% | 43 |
|
|
2018
Q1 | $563K | Buy |
2,141
+154
| +8% | +$47.8K | 0.37% | 44 |
|
|
2017
Q4 | $618K | Buy |
+1,987
| New | +$637K | 0.46% | 28 |
|
Other funds holding BIIB
VCM
VPM
Avestar Capital's BIIB Position: Q1 2026 in Review
Avestar Capital increased its Biogen (BIIB) stake by 2% in Q1 2026, buying an estimated $12.7K and bringing the position to 3,604 shares worth $661K. The position accounts for 0.04% of the portfolio, ranked #294.
Avestar Capital first reported a position in BIIB in Q4 2017 and has held it in 34 quarters since. The position peaked at $852K in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Avestar Capital held 3,604 shares of Biogen worth $661K as of Q1 2026.
- Avestar Capital bought 69 Biogen shares in Q1 2026, an estimated $12.7K.
- Biogen made up 0.04% of Avestar Capital's portfolio in Q1 2026, its #294 holding.
- Avestar Capital first reported a position in Biogen in Q4 2017 and has held it in 34 quarters since.
- Avestar Capital's Biogen position peaked at $852K in Q3 2018.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Avestar Capital's 13F filing for Q1 2026, filed 13 May 2026.